Table 2.
Current clinical trials in progress for targeted therapeutic options for gallbladder cancers (data from www.clinicaltrials.gov)
| Agent | Target | Regimen | Phase | Institution | NCI Number |
|---|---|---|---|---|---|
| Cetuximab, Trastuzumab, Gefitinib, Lapatinib, Everolimus, Sorafenib, Crizotinib | EGFR, HER2, mTOR, VEGF, ALK/ROS1, PDL-1 | GEMOX + targeted therapy per proteomic/genetic profiling | II | Xinhua Hospital, Shanghai | NCT02836847 |
| Durvalumab | PDL-1 | Guadecitabine + Durvalumab | I | University of Southern California | NCT03257761 |
| Pazopanib | cKIT, FGFR, VEGFR | Gemcitabine + Pazobanib | II | Hellenic Cooperative Oncology Group | NCT01855724 |
| Pembrolizumab | PD-1 | Pembrolizumab + Cisplatin + Gemcitabine | II | European Organization for Research and Treatment of Cancer | NCT03260712 |
| Selumetinib | MEK1, MEK2 | Selumetinib + Cisplatin + Gemcitabine | II | University Health Network, Toronto | NCT02151084 |
| ADH-1 | N-Cadherin | ADH-1 + Cisplatin + Gemcitabine | I | University of Nebraska | NCT01825603 |
| Canlisib | PI3K | Copanlisib + Cisplatin + Gemcitabine | II | H. Lee Moffitt Cancer Center and Research Institute | NCT02631590 |
| Merestinib | MET | Merestinib + Cisplatin + Gemcitabine | I | Eli Lilly and Company | NCT03027284 |
| Regorafenib | VEGF | Regorafenib | II | H. Lee Moffitt Cancer Center and Research Institute | NCT02115542 |